The United States government entered into a partial shutdown beginning December 22, 2018 at 12:01 a.m., after Congress and the Administration failed to come to an agreement on a Continuing Resolution (CR).
The Food and Drug Administration (FDA) is one of the agencies impacted by the partial government shutdown. FDA is funded through the Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act—one of the seven funding bills that Congress did not pass by the end of the 2018 fiscal year.
ASCO is urging Congress and the Administration to quickly reach a budget deal so that FDA can continue its critical work to ensure safe and effective treatments are available for patients with cancer.
ASCO has advocated for an increase in funding for FDA in Fiscal Year (FY) 2019 and supported the Administration’s request of $20 million for FDA’s Oncology Center of Excellence (OCE).
Congress has already provided funding through the end of FY 2019 for the Department of Health and Human Services (HHS), which includes funding for the National Institutes of Health (NIH) and National Cancer Institute (NCI). The funding bill included a $2 billion increase for NIH, a $79 million increase for NCI, and $400 million for the Beau Biden Cancer Moonshot for FY 2019.
Read ASCO in Action for the latest updates on federal funding for FDA and other agencies.